VALN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
VALN is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks a strong proprietary buy signal, has mixed-to-negative analyst momentum, no fresh news catalyst, and only neutral technical conditions near a pivot zone. Based on the provided data, I would not buy it now; I would wait for either clearer approval-related progress or a stronger technical setup.
The technical picture is neutral to slightly constructive but not strong enough to justify an immediate buy. MACD histogram is positive at 0.11, but it is contracting, which suggests weakening upward momentum. RSI_6 at 59.662 is neutral and not oversold. Moving averages are converging, indicating a lack of decisive trend direction. Price at 5.81 is below the pivot level of 6.033 and above support at 5.612, so the stock is trading in a tight range rather than breaking out. The provided pattern-based outlook is also mixed, with downside probability over the next week and only weak longer-term near-term return expectations.
Jefferies recently reiterated a Buy rating with a $15 price target, arguing the stock may be overreacting to the VALOR trial headline miss and that the path to approval for the Lyme disease vaccine candidate remains intact. The company still has a potential long-term catalyst from its investigational Lyme disease vaccine program if clinical or regulatory progress improves.
Goldman Sachs downgraded Valneva to Sell from Neutral and cut the target to $4.90, citing multiple data disappointments and a challenging outlook with significant uncertainty around the VALOR trial and approval path. There is no recent news flow, no significant hedge fund or insider accumulation trend, and no recent congress trading data. The lack of fresh catalysts reduces near-term momentum.
No latest-quarter financial snapshot was available in the provided data, so financial trend assessment is limited. There is no quarterly revenue, profit, or growth data to confirm improving fundamentals, which makes it difficult to support a long-term beginner buy decision from fundamentals alone.
Analyst sentiment has deteriorated recently. Goldman Sachs turned bearish with a Sell rating and $4.90 target on 2026-04-22. Guggenheim remained positive but trimmed its target to $11 from $13 on 2026-04-16 while keeping a Buy rating. Jefferies was bullish on 2026-03-23, reiterating Buy and $15, but the latest move is clearly negative because Goldman’s downgrade and cut signal weakening Wall Street confidence. Overall, Wall Street is split, but the recent trend is toward caution and downside concern.
